Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for...
RICHMOND, Va.--(BUSINESS WIRE)-- Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced that its Board of Directors declared a regular monthly cash distribution of $0.08 per common share. The distribution is payable on May 15, 2024, to shareholders of record as of April 30, 2024. Based on the Company’s common stock closing price of $14.97 on April 17, 2024, the annualized distribution of $0.96 per common share represents an annual yield of approximately 6.4%. About Apple Hospitality REIT, Inc. Apple Hospitality REIT, Inc. (NYSE: APLE) is a public...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Oc...
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that Executive Chairman, Pravin U. Dugel, MD, is assuming t...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appoin...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p
RICHMOND, Va.--(BUSINESS WIRE)-- Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced the acquisition of the 234-room AC Hotel by Marriott Washington DC Convention Center (the “Hotel”) for approximately $116.8 million, or $499,000 per key. “We are pleased to expand our portfolio with the acquisition of the AC Hotel Washington DC Convention Center and are thrilled to establish a presence in downtown Washington, D.C., a market we have tracked and wanted to have a presence in for some time,” said Nelson Knight, President, Real Estate and Investments o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.